Telo Genomics Corp (TDSGF)

Telo Genomics Corp is a Canada-based biotechnology company listed on OTC Markets as common stock. The company focuses on molecular diagnostics and the development of predictive technologies intended to help personalize treatment plans for patients with specific conditions, primarily in Canada. Its TeloView platform analyzes the three-dimensional structure and spatial organization of telomeres to provide information on genetic and molecular characteristics linked to genomic instability, disease mechanisms, risk assessment, and treatment selection. The company’s product pipeline includes TeloView-SMM for smoldering multiple myeloma patients at elevated risk of progression, TeloView NDMM for newly diagnosed multiple myeloma patients who may relapse after first-line therapy, TeloMRD-D for identifying and enumerating minimal residual disease cells in post-transplant patients, and TeloViewNG-MRD Profiling for genomic instability analysis of MRD-detected cells. Telo Genomics also has a collaboration agreement with Mayo Clinic.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.